Stay updated on Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.

Latest updates to the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedAdded revision label v3.5.0 and removed revision label v3.4.3.SummaryDifference0.0%

- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision label updated from v3.4.2 to v3.4.3. This is a non-functional update that does not change study content or user interactions.SummaryDifference0.0%

- Check36 days agoChange DetectedAdded Principal Investigator Julie Specht, MD and updated the recruiting contact at The Christ Hospital Cancer Center. Expanded the study locations to 15 sites, including Cincinnati, Ohio.SummaryDifference0.6%

- Check50 days agoChange DetectedRevision updated from v3.4.1 to v3.4.2 on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check57 days agoChange DetectedA minor revision update from v3.4.0 to v3.4.1 is displayed across the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check72 days agoChange DetectedGlossary show/hide controls were added and update-related labels were adjusted. Versioning information was updated to Revision: v3.4.0 and the previous Revision: v3.3.4 was removed, along with wording about No FEAR Act data.SummaryDifference0.3%

Stay in the know with updates to Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Sacituzumab + Pembrolizumab in Metastatic TNBC Clinical Trial page.